카테고리
조항

TSH and Thyroid MarkersNodule Testing검사 해석

TSH helps decide whether a nodule may be hormone-producing, but bloodwork rarely shows whether it is benign or malignant. Ultrasound supplies the risk pattern; ultrasound-guided tissue examination supplies cellular evidence when indicated.

게시됨 19분 분량

핵심 요점

  • 갑상선 자극 호르몬(TSH) is the first blood test for most thyroid nodules; a suppressed result below 0.1 mIU/L usually prompts a radionuclide scan rather than immediate tissue sampling.
  • 정상 TSH does not rule out thyroid cancer because most nodules, including many malignant nodules, do not change hormone production.
  • Free T4 and free T3 show thyroid function, not nodule structure; free T3 is usually most useful when TSH is low.
  • TPO and thyroglobulin antibodies support autoimmune thyroid disease but cannot classify a solitary nodule as benign or malignant.
  • 칼시토닌 may help detect medullary thyroid carcinoma in selected people, especially with a family history or MEN2 risk, but routine testing remains debated.
  • 초음파 assesses composition, echogenicity, margins, shape, calcification and lymph nodes; these features determine whether follow-up or tissue examination is appropriate.
  • Fine-needle aspiration is generally guided by ultrasound pattern and size, with common thresholds ranging from about 1 cm for high-suspicion nodules to 2.5 cm for low-suspicion nodules.
  • 분자 검사 is mainly an add-on for indeterminate cytology; it does not replace ultrasound, clinical assessment or pathology review.

Which thyroid nodule results matter first?

TSH, ultrasound appearance and cytology matter most, but they answer different questions. TSH shows whether the thyroid is being over- or under-stimulated; ultrasound estimates structural risk; tissue examination evaluates cells. A normal TSH cannot classify most nodules, and a blood test alone cannot reliably distinguish a benign nodule from cancer.

Thyroid nodule blood test results beside a detailed thyroid anatomy model
A thyroid anatomy model introduces the separate roles of bloodwork and imaging.

The average adult has a thyroid nodule risk of roughly 4% to 7% by palpation, while ultrasound detects nodules in far more people because it sees very small findings. Only about 5% to 15% of clinically recognized nodules prove malignant, depending on the population and referral setting.

The 2015 American Thyroid Association guideline recommends serum TSH as the initial laboratory test for a known nodule, then uses the result to decide whether radionuclide imaging is appropriate (Haugen et al., 2016). The reason is physiological: a nodule making thyroid hormone can appear different on a scan from a non-functioning nodule.

Kantesti is an AI blood test analyzer that can organize TSH, free T4, free T3, antibodies and calcitonin into a readable pattern, but our interpretation cannot replace a neck ultrasound or a clinician's examination. Start with the 혈액검사 바이오마커 가이드 when you need help identifying which result belongs to which panel.

What does TSH reveal about a thyroid nodule?

TSH is the key first blood result because a low value may indicate an autonomous, hormone-producing nodule. Many laboratories use an adult reference interval near 0.4 to 4.0 mIU/L, although the interval printed on your report takes priority and may differ by assay, age and pregnancy.

Thyroid nodule blood test workflow showing TSH laboratory sample processing
A TSH testing workflow shows why hormone status guides the next investigation.

A TSH below 0.1 mIU/L is called suppressed and increases the likelihood that at least one nodule is autonomously functioning, particularly when free T4 or free T3 is high. A TSH between 0.1 and 0.39 mIU/L is mildly low and deserves context rather than an automatic diagnosis.

A high TSH does not make a nodule benign. In Hashimoto thyroiditis, TSH may rise while the gland becomes heterogeneous and nodular, and the inflammatory background can make ultrasound interpretation more difficult. A practical review of testing intervals is available in our guide to how often thyroid levels are checked.

Suppose a hypothetical 62-year-old has a TSH of 0.06 mIU/L, free T4 within range and a 1.8 cm nodule. The result suggests subclinical hyperthyroidism and may justify a radionuclide scan; it does not prove cancer, and it does not automatically justify tissue examination before functional imaging.

참고 범위
수준범위의미
를 통해 검토용으로 업로드할 수 있습니다.0.4-4.0mIU/LThyroid stimulation is broadly within the laboratory interval; ultrasound still determines nodule risk.
경도 상승4.1-10.0 mIU/LMay suggest subclinical hypothyroidism if free T4 remains normal; it does not identify nodule type.
현저히 상승10-20 mIU/LOften warrants clinical assessment for hypothyroidism, medication effects or autoimmune disease.
Suppressed<0.1 mIU/LSuggests strong thyroid stimulation or excess hormone and commonly prompts radionuclide scanning.

How do free T4 and free T3 change interpretation?

Free T4 and free T3 show whether the thyroid is producing excess or insufficient hormone, but neither test describes the nodule's ultrasound structure. Free T4 is usually the more useful companion to TSH; free T3 becomes especially informative when TSH is low and free T4 is still normal.

Thyroid nodule blood test markers represented by free T4 and T3 laboratory analysis
Free thyroid hormones explain function but cannot display nodule architecture.

High free T4 with a suppressed TSH supports overt thyrotoxicosis, while normal free T4 with a suppressed TSH supports a subclinical pattern. T3 toxicosis occurs when free or total T3 is high despite a normal free T4, so a normal T4 does not always end the assessment.

Free hormone reference intervals vary substantially; one adult laboratory may report free T4 as approximately 10 to 22 pmol/L, while another uses 0.8 to 1.8 ng/dL. The conversion is not the main issue: assay method, pregnancy, binding proteins and biotin use can shift results, which is why T4 and T3 meanings should be read beside the local range.

Imagine a hypothetical result with TSH 0.08 mIU/L, free T4 15 pmol/L and free T3 8.1 pmol/L when the upper limit is 6.8. That pattern raises concern for T3-predominant hormone excess and may explain palpitations, but it still cannot tell whether the responsible nodule is structurally suspicious.

What can thyroid antibodies reveal?

TPO and thyroglobulin antibodies indicate autoimmune thyroid activity; they do not grade the cancer risk of an individual nodule. TPO antibody positivity supports Hashimoto disease or, in another clinical pattern, autoimmune hyperthyroidism, but antibody concentration does not translate into a nodule score.

Thyroid nodule blood test antibody assay with molecular immune markers in focus
Antibody testing can reveal autoimmunity while leaving nodule structure unresolved.

TPO antibody results are often reported as positive above a laboratory-specific cutoff such as 34 IU/mL, but cutoffs differ between assays. A positive result means immune recognition of thyroid proteins; it does not mean that a nodule is malignant, and a negative result does not exclude every form of thyroid disease.

Thyroglobulin antibodies can interfere with thyroglobulin measurement, sometimes producing a misleadingly low or occasionally unpredictable thyroglobulin result. This matters most after thyroid cancer treatment, when thyroglobulin is used for surveillance rather than for initial assessment of an untreated nodule.

Kantesti AI interprets thyroid antibody results beside TSH and free hormone values rather than treating a positive antibody as a cancer marker. If your report contains several antibody flags, compare the pattern with our explanation of 양성 항체 결과 and discuss ultrasound findings separately.

Does thyroglobulin diagnose a thyroid nodule?

Serum thyroglobulin is not recommended as a routine diagnostic blood test for an untreated thyroid nodule. Thyroglobulin is produced by normal thyroid tissue as well as differentiated thyroid cancer, so a high value usually reflects the amount of thyroid tissue, inflammation, iodine status or other context rather than a specific diagnosis.

Thyroid nodule blood test showing thyroglobulin assay beside a thyroid cross-section
Thyroglobulin reflects thyroid tissue activity but cannot classify most nodules.

A thyroglobulin concentration of 40 ng/mL, for example, cannot be called cancerous without knowing the remaining thyroid volume, TSH, iodine exposure and antibody status. The number is more clinically useful after total thyroid removal and radioactive iodine treatment, when detectable thyroglobulin may signal residual or recurrent differentiated tissue.

The reverse mistake also occurs: a low thyroglobulin does not prove that a nodule is harmless. Small nodules may release little protein, and thyroglobulin antibodies can distort the assay. This is one reason clinicians prefer ultrasound risk features and, when indicated, cytology over a single serum marker.

The relationship between albumin, globulins and antibody interference is explained in this 혈청 단백질 연구 가이드. The practical rule is simple: do not order thyroglobulin merely because a nodule was seen unless a specialist has identified a specific surveillance question.

When does a calcitonin thyroid test help?

A calcitonin thyroid test can support evaluation for medullary thyroid carcinoma, but routine testing of every nodule remains an area of guideline disagreement. A persistently elevated basal calcitonin above about 100 pg/mL is strongly concerning in the right clinical setting, whereas modest elevations require assay, kidney, medication and smoking context.

Calcitonin thyroid test laboratory assay with carefully arranged endocrine samples
Calcitonin testing is most useful when medullary cancer risk is clinically plausible.

Calcitonin is produced by thyroid C cells, the cell type involved in medullary thyroid carcinoma. Values below 10 pg/mL are often reassuring, values from approximately 10 to 100 pg/mL are difficult to interpret, and values above 100 pg/mL are much more suspicious; these are practical guideposts, not universal diagnostic cutoffs.

The evidence is honestly mixed on population-wide screening because assay thresholds, false positives and downstream surgery differ across countries. Kidney impairment, autoimmune thyroid disease, proton-pump inhibitor use through gastrin effects, smoking and some neuroendocrine conditions can raise calcitonin without medullary cancer.

A family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, a suspicious lymph-node pattern or a markedly elevated result makes specialist evaluation more urgent. Our 의학적 검증 정보 explains why an AI interpretation can organize this context but cannot confirm a rare thyroid cancer.

Why is ultrasound central to thyroid nodule tests?

Ultrasound is the main test for classifying a thyroid nodule because it shows composition, echogenicity, margins, shape, calcification and cervical lymph nodes. Bloodwork describes thyroid function; ultrasound shows the physical pattern that determines whether monitoring or ultrasound-guided tissue examination is appropriate.

Thyroid nodule tests shown through a professional neck ultrasound examination
Ultrasound reveals the structural features that blood tests cannot measure.

A solid hypoechoic nodule with irregular margins, punctate echogenic foci or a taller-than-wide shape carries more concern than a spongiform or purely cystic nodule. Suspicious lymph nodes may show rounded shape, loss of the fatty hilum, cystic change or abnormal vascular features, and they can change the sampling plan.

Size alone is not a cancer diagnosis. A 2.5 cm spongiform nodule may be monitored while a 0.9 cm nodule with extrathyroidal extension or suspicious nodes may require tissue examination; the reason for the difference is risk pattern, not simply diameter.

Kantesti is an AI blood test interpretation platform, not an ultrasound reader, so a blood report cannot substitute for the written imaging score and stored ultrasound images. Ask for the nodule's three dimensions, composition, echogenicity, margins, calcification description and lymph-node assessment rather than accepting only the word "nodule."

How do TI-RADS categories affect the next step?

TI-RADS systems convert ultrasound features into a risk category and size-based recommendation; they do not use TSH or antibody results to calculate the score. In the ACR system, a TR5 nodule commonly reaches tissue-examination criteria at 1.0 cm, while TR3 nodules generally reach that threshold at 2.5 cm.

Thyroid nodule test comparison showing ultrasound risk patterns from low to high concern
Ultrasound risk categories combine several features rather than relying on size alone.

Typical ACR TI-RADS thresholds are TR5: tissue examination at 1.0 cm and follow-up at 0.5 cm; TR4: tissue examination at 1.5 cm and follow-up at 1.0 cm; and TR3: tissue examination at 2.5 cm and follow-up at 1.5 cm. TR1 and TR2 findings usually need no sampling.

The 2017 ACR TI-RADS publication by Tessler and colleagues describes this point-based approach, which aims to reduce unnecessary procedures while catching higher-risk patterns. Other systems, including ATA categories and European scoring methods, use different wording and thresholds, so two legitimate reports may recommend different follow-up for the same nodule (Tessler et al., 2017).

A hypothetical 1.2 cm TR5 nodule meets a common sampling threshold, while a hypothetical 1.2 cm TR3 nodule does not. You can read more about low-TSH patterns in our guide to 무증상(잠재성) 갑상선기능항진증, because functional status may determine whether scanning comes before sampling.

When is tissue examination or FNA needed?

Ultrasound-guided fine-needle aspiration is considered when the nodule's sonographic risk and size cross a guideline threshold, or when suspicious lymph nodes or symptoms change the risk calculation. It is not automatically required for every nodule, and a low TSH may lead to a radionuclide scan first.

Thyroid nodule tissue examination prepared with ultrasound guidance in a calm clinic
Ultrasound-guided tissue examination samples cells when structural risk justifies it.

Common ATA size thresholds are about 1 cm for high- or intermediate-suspicion nodules, 1.5 cm for low-suspicion nodules and 2 cm for very-low-suspicion nodules, although patient preference and local practice matter. A purely cystic nodule often does not need diagnostic aspiration unless it causes pressure or requires drainage.

Cytology is reported using Bethesda categories. Bethesda I means nondiagnostic and may lead to repeat sampling; Bethesda III and IV are indeterminate; Bethesda V is suspicious; and Bethesda VI is malignant. Reported malignancy risks vary by institution and whether non-invasive follicular thyroid neoplasm is counted as cancer, so a category should never be interpreted without the laboratory's stated risk range.

A palpable rapidly enlarging mass, hoarseness, difficulty swallowing, breathing symptoms or a firm neck lymph node warrants prompt medical assessment even if TSH is normal. Our page on the 의료 자문 위원회를 describes the role of clinical oversight, but only your treating team can decide whether sampling is safe and appropriate.

What do molecular thyroid nodule tests add?

Molecular thyroid nodule tests are mainly useful when cytology is indeterminate; they are not a replacement for ultrasound or an initial blood panel. Gene-expression or mutation panels can shift the estimated probability of cancer, helping some patients choose surveillance rather than diagnostic surgery, but performance depends on the test, prevalence and laboratory validation.

Thyroid nodule molecular test workflow arranged from tissue sample to genetic analysis
Molecular testing can refine an indeterminate cytology result after sampling.

A negative molecular result may reduce the estimated cancer probability to a level compatible with surveillance, while a positive result may increase concern; neither result is an absolute yes-or-no diagnosis. A test with a 95% negative predictive value in one population may perform differently where the pre-test cancer prevalence is 10% rather than 30%.

The result must be matched to Bethesda category, ultrasound pattern, age, radiation history and family history. Molecular testing is often less useful for a clearly benign or clearly malignant cytology result because those results already provide stronger direction.

Kantesti AI can help place a molecular report beside the ordinary laboratory values and imaging summary, but our AI 기술 가이드 explains why algorithmic pattern recognition does not independently validate a proprietary genomic assay. Ask which genes were assessed, what population was studied and whether the lab reports sensitivity, specificity and predictive values.

When is a thyroid scan better than immediate FNA?

A radionuclide thyroid scan is especially useful when TSH is below the reference interval because it shows whether a nodule is hyperfunctioning, isofunctioning or nonfunctioning. A clearly hyperfunctioning nodule is rarely malignant and often does not need diagnostic tissue examination, although the final plan depends on the scan and ultrasound together.

Thyroid nodule tests showing a radionuclide scan concept beside a functional thyroid model
Functional imaging distinguishes hormone-producing nodules from nonfunctioning areas.

A low TSH of 0.05 mIU/L with a focal area of increased tracer uptake suggests autonomy, while a normal or high TSH usually makes radionuclide scanning less urgent. Scan findings do not erase suspicious ultrasound features; a functioning nodule can still require review if its structure or lymph nodes are atypical.

Symptoms of hormone excess may include resting palpitations, heat intolerance, tremor or unexplained weight loss, but symptoms are not required. Persistent TSH suppression below 0.1 mIU/L matters more in adults over 65 and in people with osteoporosis or cardiac disease because untreated hormone excess can increase atrial-fibrillation and bone-loss risk.

Total T3 can reveal hormone excess when free T4 is normal, as explained in our total T3 testing guide. Do not stop thyroid medication or iodine-containing treatment before a scan without specific instructions, because preparation can alter tracer uptake and make the result harder to interpret.

How do pregnancy, age and history change testing?

Pregnancy, childhood, prior neck radiation and a family history of thyroid cancer lower the threshold for specialist assessment, but they do not make every nodule malignant. The same TSH number can carry different implications during pregnancy, in older adults or after exposure to medicines that alter thyroid function.

Thyroid nodule test consultation showing pregnancy-safe ultrasound and laboratory review
Clinical context changes how thyroid blood results and imaging are interpreted.

Pregnancy-specific TSH ranges are preferred, and radioactive iodine scanning is avoided during pregnancy. Ultrasound remains the main structural test, while free T4 interpretation requires a pregnancy-appropriate assay or reference interval because binding proteins change during gestation.

Children and adolescents with thyroid nodules generally receive more cautious evaluation because malignancy risk is higher than in adults, even though nodules are less common. A history of external neck radiation, familial medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should be stated before testing because it can change the choice of calcitonin, genetic counselling and ultrasound follow-up.

A family history is not the same as proof of inherited disease. For practical thyroid nutrition context, see our diet and thyroid health guide, but avoid high-dose iodine or kelp supplements without advice because excess iodine can destabilize thyroid function in susceptible people.

Which symptoms make follow-up more urgent?

Rapid enlargement, persistent hoarseness, swallowing difficulty, breathing difficulty or a new firm lymph node requires prompt clinical assessment, regardless of a normal thyroid nodule blood test. These features can indicate compression, vocal-cord involvement or lymph-node disease, although benign conditions can also produce neck pressure.

Thyroid nodule blood test follow-up scene with neck ultrasound referral and clinical notes
Warning symptoms can accelerate assessment even when bloodwork appears reassuring.

A normal TSH near 2.0 mIU/L does not reduce a suspicious ultrasound pattern to low risk. Conversely, a suppressed TSH of 0.08 mIU/L may point toward an autonomous nodule rather than cancer, so urgency depends on the combination of symptoms, examination, scan and ultrasound.

Follow-up intervals are risk-based rather than universal. A small, low-suspicion nodule may be re-imaged after 12 to 24 months, while a suspicious nodule or abnormal lymph node may be assessed sooner; meaningful growth is often defined as at least 20% increase in two dimensions with a minimum 2 mm increase, or more than 50% increase in volume.

저희 서비스를 이용하세요 갑상선 검사 일정 as a preparation aid, not a substitute for a personalised plan. Seek urgent care for breathing difficulty, rapidly worsening neck swelling or inability to swallow fluids rather than waiting for a repeat blood result.

How should all thyroid nodule results be combined?

The safest interpretation combines TSH, free hormones, selected antibodies, ultrasound pattern, size, symptoms and cytology instead of ranking one abnormal number above everything else. Bloodwork answers whether the gland is functioning abnormally; imaging answers what the nodule looks like; tissue examination answers what cells are present.

Thyroid nodule blood test report integrated with ultrasound and cytology review
Integrated review prevents a single reassuring or abnormal result from misleading you.

A practical sequence is: confirm the nodule and ultrasound details; measure TSH; add free T4 and sometimes free T3; consider antibodies when autoimmune disease is plausible; consider calcitonin when medullary cancer risk justifies it; then use scanning, tissue examination or surveillance according to the pattern.

Kantesti is an AI-powered blood test analysis tool that can compare current TSH and thyroid-marker results with prior reports, identify changes such as TSH falling from 1.8 to 0.12 mIU/L, and highlight questions for a clinician. It cannot inspect ultrasound images, determine cytology quality or make a cancer diagnosis from bloodwork.

For trustworthy interpretation, keep the laboratory reference ranges, medication list, supplement list, pregnancy status, prior imaging and exact nodule dimensions together. Our 임상 감독 표준 explain how medical information should be framed, while the research guide on serum proteins illustrates why assay context matters.

What can a thyroid nodule blood test not tell you?

A thyroid nodule blood test cannot reliably tell whether most nodules are benign, malignant, cystic, solid or compressive. Even an entirely normal panel can coexist with a suspicious ultrasound finding, while several abnormal blood results may reflect autoimmune disease or medication effects rather than a dangerous nodule.

TSH is a function marker, not a cancer screen. Thyroglobulin is a thyroid-tissue marker, not a general nodule test; TPO antibodies indicate immune activity, not malignancy; and calcitonin is a specialised marker whose interpretation depends on assay and pre-test risk.

Biotin supplements can interfere with some immunoassays, sometimes making TSH appear falsely low and free T4 or T3 falsely high. Ask the ordering clinician or laboratory whether biotin should be paused before testing; do not stop prescribed medicines independently, and disclose high-dose hair, skin and nail products.

Kantesti AI can explain why a result is flagged and compare it with previous values, but our platform cannot overrule an ultrasound recommendation or a cytology report. If the report is confusing, ask for the clinical question being answered: function, autoimmune activity, medullary cancer risk, structural risk or postoperative surveillance.

What should you bring to a thyroid nodule appointment?

Bring the complete laboratory report, ultrasound report, medication list, supplement list and relevant family or radiation history. A single number without its unit, reference interval and collection date can lead to a wrong conclusion, especially for calcitonin, free hormones and antibody assays.

Write down the exact TSH value, free T4 and free T3 units, antibody names, calcitonin assay and reference range. Include whether you take levothyroxine, antithyroid medication, lithium, amiodarone, iodine supplements or biotin because these can alter thyroid results or their interpretation.

Ask five focused questions: What is the ultrasound risk category? What are the nodule dimensions in millimetres? Are lymph nodes suspicious? Does TSH require a radionuclide scan? If cytology is indeterminate, would molecular testing change management? These questions often provide more useful information than asking whether a single blood result is "normal."

You can upload a laboratory PDF or photograph to Kantesti for an organised explanation of the blood results, then take the questions to your clinician. Keep privacy in mind and review our data security information before sharing health documents online.

What is the bottom line for thyroid nodule testing?

TSH is the most useful first blood result, but ultrasound usually determines structural risk and tissue examination confirms cellular diagnosis when indicated. A normal TSH is reassuring about thyroid function, not a guarantee that the nodule is harmless; a low TSH may redirect testing toward a radionuclide scan.

The most actionable pattern is not one isolated flag but a coherent combination: suppressed TSH plus a focal hot nodule; normal TSH plus a high-suspicion ultrasound pattern; positive TPO antibodies plus diffuse gland changes; or elevated calcitonin plus a family history of medullary thyroid carcinoma.

The two DOI-linked Kantesti research guides listed below concern broader laboratory interpretation rather than thyroid nodule diagnosis, so they should not be used as substitutes for thyroid guidelines. For questions about clinical review and responsible interpretation, consult the Kantesti 의료 자문 위원회.

If your result is abnormal, the next step is usually clarification rather than panic: verify the assay and reference range, review medicines and supplements, obtain the full ultrasound description, and ask whether repeat bloodwork, scanning, follow-up imaging or tissue examination answers the remaining question.

자주 묻는 질문

혈액 검사로 갑상선 결절이 암성인지 알 수 있나요?

혈액검사만으로는 대부분의 갑상선 결절이 암성인지 신뢰성 있게 판단할 수 없습니다. TSH, 유리 T4 및 유리 T3는 갑상선 기능을 평가하고, TPO 및 티로글로불린 항체는 자가면역 또는 검사 관련 맥락을 평가하지만, 어느 것도 일반적인 암 진단을 제공하지는 않습니다. 초음파는 구조적 위험을 평가하며, 결절이 크기 및 모양 기준을 충족하는 경우 초음파 유도 조직 검사가 필요할 수 있고, 고위험 의심 결절의 경우 대개 약 1cm를 기준으로 합니다.

갑상선 결절에서 어느 TSH 수치가 우려되나요?

0.1 mIU/L 미만의 TSH는 억제된 상태이며, 결절이 독립적으로 호르몬을 생성하고 있을 수 있으므로 일반적으로 방사성핵종 갑상선 스캔을 고려하게 됩니다. 0.1~0.39 mIU/L의 TSH는 경미하게 낮은 수치로, 맥락을 파악하기 위해 free T4, free T3, 증상 및 반복 검사가 필요합니다. 약 0.4~4.0 mIU/L의 정상 TSH라고 해서 갑상선암을 배제할 수 없으며 초음파 검사의 필요성도 없어지지 않습니다.

모든 갑상선 결절에서 칼시토닌을 검사해야 하나요?

모든 갑상선 결절에 대한 정례적 칼시토닌 검사는 분석법의 기준치와 위양성 결과가 다양하기 때문에 여전히 논란이 있습니다. 칼시토닌 수치가 약 100 pg/mL를 지속적으로 초과하면 갑상선 수질암이 강하게 의심되지만, 10~100 pg/mL 정도의 결과는 임상적 맥락과 재검사 또는 전문의 평가가 필요합니다. 갑상선 수질암의 가족력, MEN2 위험 또는 임상적으로 의심스럽고 초음파상 의심스러운 양상이 있는 경우 검사와 특히 관련이 있습니다.

Does a normal thyroid blood test mean a nodule is benign?

A normal thyroid blood test means thyroid hormone production is broadly within the laboratory interval; it does not prove that a nodule is benign. Many benign and malignant nodules occur with TSH around 0.4 to 4.0 mIU/L and normal free T4. Ultrasound features, nodule size, lymph nodes and cytology determine structural and cellular risk.

When is a thyroid nodule biopsy needed?

Tissue examination is usually considered when ultrasound risk and nodule size cross a guideline threshold or when suspicious lymph nodes or symptoms increase concern. Common thresholds range from about 1 cm for high-suspicion nodules to 2.5 cm for low-suspicion nodules, depending on the scoring system. A low TSH may lead to radionuclide scanning first, because a clearly hormone-producing nodule often does not need immediate diagnostic aspiration.

Do thyroid antibodies make a nodule more likely to be cancer?

TPO and thyroglobulin antibodies primarily indicate autoimmune thyroid activity and do not directly classify an individual nodule as malignant. A TPO antibody result above a laboratory cutoff such as 34 IU/mL can support autoimmune thyroid disease, but cutoffs vary by assay. The nodule still requires ultrasound-based assessment, and thyroglobulin antibodies can interfere with thyroglobulin measurement.

Can Kantesti interpret thyroid nodule blood test results?

Kantesti can organise and explain thyroid blood results such as TSH, free T4, free T3, TPO antibodies, thyroglobulin antibodies and calcitonin in relation to the laboratory reference ranges. It can compare trends, identify combinations that deserve clinical review and help prepare questions, but it cannot read ultrasound images, validate cytology or diagnose thyroid cancer. A result such as TSH below 0.1 mIU/L still requires clinician-directed assessment of medication, symptoms and possible functional imaging.

혈액검사 결과 보는법

검사실 보고서를 업로드하면 Kantesti의 AI가 몇 초 안에 각 바이오마커를 쉬운 말로 설명합니다. 전 세계 200만 명 이상이 사용하고 있습니다.

참고 자료

  1. Klein, T., Mitchell, S., & Weber, H. (2026). 혈청 단백질 안내서: 글로불린, 알부민 및 A/G 비율 혈액검사. Kantesti AI 의학 연구. DOI
  2. Klein, T., Mitchell, S., & Weber, H. (2026). C3 C4 보체 혈액 검사 및 ANA 역가 가이드. Kantesti AI 의학 연구. DOI
  3. Haugen BR et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. 갑상선. DOI 퍼브메드
  4. Tessler FN et al. (2017). ACR Thyroid Imaging, Reporting and Data System (TI-RADS): White Paper of the ACR TI-RADS Committee. 미국영상의학회지. DOI 퍼브메드
  • 200만+분석한 검사
  • 127+국가
  • 100+언어

의료진 소개

prof dr thomas klein 최고 의료 책임자 cmo kantesti ai

토마스 클라인, 의학박사

주 저자 · 의학 검토자

칸테스티 AI 최고 의료 책임자

Thomas Klein 박사는 15년 이상의 검사실 의학 및 AI 보조 임상 분석 경험을 갖춘 보드 인증 임상 혈액학자이자 내과 전문의입니다.

임상병리학 수석 의료 자문위원 사라 미첼 박사

사라 미첼, 의학박사, 철학박사

의료 자문가

수석 의료 자문위원 - 임상병리학 및 내과

Dr. Sarah Mitchell은 18년 이상의 실험실 의학 및 진단 분석 경험을 가진 보드 인증 임상 병리학자입니다. 임상 화학 분야의 전문 자격을 보유하고 있으며, 임상 실무에서 바이오마커 패널과 실험실 분석에 대해 광범위하게 출판해 왔습니다.

검사 의학 수석 의료 자문위원 한스 베버 교수

한스 베버 교수 (박사)

기고 전문가

임상병리학 및 임상생화학 교수

Prof. Dr. Hans Weber는 임상 생화학, 실험실 의학, 바이오마커 연구 분야에서 30년 이상의 전문성을 갖고 있습니다. 독일 임상화학회 전 회장으로서, 진단 패널 분석, 바이오마커 표준화, AI 보조 실험실 의학을 전문으로 합니다.

E-E-A-T 신뢰 신호

경험

의사가 주도하는 검사 해석 워크플로 임상 검토.

전문적 지식

임상 맥락에서 바이오마커가 어떻게 거동하는지에 대한 검사실 의학 중심.

권위

Thomas Klein 박사의 의학적 검토를 거쳤으며, Sarah Mitchell 박사와 Hans Weber 교수의 기여가 있었습니다.

신뢰성

경고를 줄이기 위한 명확한 후속 경로가 포함된 근거 기반 해석.

의학적 면책 조항

이 글은 교육 목적만을 위한 것이며 의학적 조언을 구성하지 않습니다. 진단 및 치료 결정에는 항상 자격을 갖춘 의료 전문가와 상담하세요.

게시됨 · 편집팀에 문의

Kantesti Ltd 발행, 잉글랜드 및 웨일스에 등록된 회사, 회사 번호. 17090423, 런던, 영국.

Prof. Dr. Thomas Klein에 의해

Thomas Klein 박사는 Kantesti AI의 최고 의료 책임자(CMO)로 재직 중인 보드 인증 임상 혈액종양내과 전문의입니다. 실험실 의학 분야에서 15년 이상의 경험을 보유하고 있으며, 혈액검사 결과의 AI 지원 해석에 큰 관심을 가지고 있습니다. 그는 새로운 기술을 일상적인 임상 진료와 연결하기 위해 노력합니다. 그의 관심 분야에는 생체표지자 분석, 임상 의사결정 지원 연구, 인구집단별 기준 범위 최적화가 포함됩니다. CMO로서 그는 플랫폼의 내부 벤치마킹에 대한 임상적 의견을 제공하고, Kantesti의 교육 보고서에 대한 의학적 품질에 대해 임상적 감독을 제공합니다.

답글 남기기

이메일 주소는 공개되지 않습니다. 필수 필드는 *로 표시됩니다